The BCL6 product consists of a 461kb probe, labelled in red, telomeric to the BCL6 gene, and two green probes, 366kb and 165kb, centromeric to the BCL6 gene.
Rearrangements of the BCL6 gene have been observed in 28.6-35.5% of Diffuse Large B-Cell Lymphoma (DLBCL) and in 6.4-14.3% of Follicular Lymphoma (FL)1.
This translocation results in the dysregulation of BCL6 and may involve the IGH, IGK and IGL genes, although other non-Ig partner genes have also been identified2,3. BCL6 encodes a 95kD nuclear phosphoprotein belonging to the pox virus zinc finger (POZ)/zinc finger (ZF) family of transcription factors4. BCL6 functions as a transcriptional repressor and plays an important regulatory role in lymphoid cell development and function. In the B-cell lineage, the BCL6 protein is expressed only in germinal centre B cells5. Translocations involving band 3q27.3 affect a 4kb major breakpoint region of BCL6 in the first non-coding exon and 5' region of the first intron, and are common in diffuse large B-cell lymphomas. Recently, an alternative breakpoint cluster region located between 245 and 285kb 5' of BCL6 was identified in Non-Hodgkin Lymphoma (NHL) and may be preferentially associated with follicular lymphoma6.
The quality and reproducibility of results using the CytoCell kit has been vital in accurately detecting co-deletions in our glioma investigations. We now have a cost-effective test that we can rely on that is also easy to use and interpret. We've been consistently impressed with this kit - not to mention the support offered by OGT's customer service, and have completely transitioned over to CytoCell probes.
Gavin Cuthbert, FRCPath
Head of Cancer Cytogenetics, Northern Genetics Service, Newcastle, UK